Atypical Depression

  title={Atypical Depression},
  author={Chi-Un Pae and Haresh M. Tharwani and David M. Marks and Prakash S. Masand and Ashwin A. Patkar},
  journal={CNS Drugs},
Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain laterality, psychological profile and psychiatric co-morbidity and differential treatment response. The evolution of the diagnostic criteria for atypical depression has led to the… 

Heterogeneity in major depression and its melancholic and atypical specifiers: a secondary analysis of STAR*D

No evidence is found that the atypical and melancholic specifiers create more symptomatically homogeneous groups, as can be quantified by unique symptom profiles, which are introduced by adding symptoms to the DSM diagnosis of MDE.

Meta-review of depressive subtyping models.

Clinical features of atypical depression in bipolar and recurrent affective disorders, psychogenic depression

The identified features of the clinical picture and course of AtD in BAD, RDR, and PD can be used for earlier and more accurate evaluation of affective disorders and the adequate treatment administration.

Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study.

Major Depressive Disorder

Depressive symptoms are highly prevalent in MDD, occurring in up to 80% of patients, and patients with mood disorders suffer a higher risk of suicide relative to the general population.

General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry

The spectrum of different antidepressant treatments has broadened over the last few decades and the efficacy and clinical effectiveness of antidepressants is statistically significant, clinically relevant, and proven repeatedly.

Challenges for PET Neuroimaging of Depressive Disorders

This chapter deals with two major challenges facing PET neuroimaging of depressive disorders: determining the neurobiology of depressive disorders and inventing suitable positron-emitting



Depression With Atypical Features: Diagnostic Validity, Prevalence, and Treatment.

  • F. Quitkin
  • Psychology, Medicine
    Primary care companion to the Journal of clinical psychiatry
  • 2002
A growing body of evidence suggests this is a biologically distinct subtype of depression, supported by genetic epidemiologic studies and by a preferential response of the subtype to monoamine oxidase inhibitors compared with tricyclic antidepressants.

A history of the concept of atypical depression.

  • J. Davidson
  • Psychology
    The Journal of clinical psychiatry
  • 2007
The term atypical depression as a preferentially monoamine oxidase inhibitor (MAOI)-responsive state was first introduced by West and Dally in 1959, and in this "post- MAOI" era, no novel compound or group of drugs has been clearly shown to have good efficacy in atypicals depression, leaving the treatment of atypICAL depression as an unmet need.

Recognition and diagnosis of atypical depression.

  • M. Thase
  • Psychology
    The Journal of clinical psychiatry
  • 2007
The utility of the atypical depression subtype for differential therapeutics diminished substantially when the TCAs were supplanted as first-line antidepressants by the selective serotonin reuptake inhibitors and introduction of safer MAOIs has fostered renewed interest in atypicals depression.

Atypical depression: a valid subtype?

  • G. Parker
  • Psychology
    The Journal of clinical psychiatry
  • 2007
A model challenging the DSM-IV-TR definition of atypical depression has been developed, redefining the disorder as a dimensional nonmelancholic syndrome in which individuals with a personality subtype of "interpersonal rejection sensitivity" have a tendency toward the onset of anxiety disorders and depression, thereby exhibiting a variety of dysregulated emotional and self-consolatory responses.

Course and treatment of atypical depression.

Monoamine oxidase inhibitors (MAOIs) are superior to tricyclic antidepressants (TCAs) for the treatment of atypical depression, but few studies have compared MAOIs to the newer generation of antidepressants (SSRIs, bupropion, venlafaxine, nefazodone, and mirtazapine).

Atypical depression: clinical aspects and noradrenergic function.

The data support the inclusion of atypical depression as a subtype of the depressive disorders in DSM-IV, as well as earlier studies, which suggest a less impaired biological system than nonatypical Depression.

Partial validation of the atypical features subtype of major depressive disorder.

The results provide partial support for the validity of the atypical features subtype of major depressive disorder.

Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.

Pharmacologic dissection suggests that atypical symptoms in patients with nonautonomous mood may delineate a qualitatively distinct subgroup.